Tag: GlobeNewswire

MILWAUKEE, Nov. 02, 2026 (GLOBE NEWSWIRE) — Twin Disc, Inc. (NASDAQ: TWIN) today announced that the Board of Directors (the “Board”) approved a regular quarterly cash dividend of $0.05 per share payable on December 1, 2026, to shareholders of record at the close of business on November 18, 2026.

About Twin Disc

Twin Disc, Inc. designs, manufactures, and sells marine and heavy-duty off-highway power transmission equipment. Products offered include: marine transmissions, azimuth drives, surface drives, propellers, and boat management systems, as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, control systems, and braking systems. The Company sells its products to customers primarily in the pleasure craft, commercial and military marine markets, as well as in the energy and natural resources, government, military and industrial markets. The Company’s worldwide sales to both domestic and foreign customers are transacted through a direct sales force and a distributor network. For more information, please visit www.twindisc.com.

Investors:

IMS Investor Relations

twindisc@imsinvestorrelations.com

Source: Twin Disc, Incorporated

• CEO Roger M. Perlmutter, M.D., Ph.D., to participate in Guggenheim 3^rd Annual Healthcare Innovation Conference Fireside Chat and JP Morgan Biotech Call series
• CMO Roy Baynes, M.D., Ph.D., to participate in Morgan Stanley Biotech Webcast discussing new data and the evolving synthetic lethality landscape

MILLBRAE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) — Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon Therapeutics, will participate in the JP Morgan Chase Biotech Call series and a Guggenheim Investor Conference as listed below:

Event: JP Morgan Biotech Call Series
Location: Boston, MA
Date & Time: November 6, 2026 at 2:00 pm EST
Format: Presentation

Event: Guggenheim 3rd Annual Healthcare Innovation Conference
Location: Boston, MA
Date & Time: November 10, 2026 at 8:00 pm EST
Format: Fireside Chat

In addition, Chief Medical Officer, Roy Baynes, M.D., Ph.D., will participate in the Morgan Stanley Biotech Webcast in November:

Event: Post-ESMO: New Data & the Evolving Synthetic Lethality Landscape
Location: New York City, NY
Date & Time: November 3, 2026 at 10:30 am EST
Format: Call

Live audio/video webcasts of these presentations will be accessible through Eikon’s investor relations website at investors.eikontx.com, with an archived edition of the session available later that day and accessible for approximately 30 days after the live event.

About Eikon Therapeutics
Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully integrated organization developing innovative medicines to address serious unmet medical needs. Eikon’s initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers. Eikon deploys its technology platform, including its proprietary single molecule tracking system, to develop internally derived novel therapies, while also leveraging the deep expertise of its management team to in-license promising assets. Eikon’s vision is to become a generational leader by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. For more information, visit www.eikontx.com.

Forward-Looking/Safe Harbor Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts are hereby identified as forward-looking statements for this purpose. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the therapeutic potential, safety, and efficacy of Eikon’s product candidates; the potential to further develop Eikon’s product candidates; the timing for anticipated data readouts; expected milestones and business objectives, including Eikon’s anticipated presentations at the 2026 ESMO Congress; and other statements regarding Eikon’s future operations, financial performance, financial position, prospects, objectives, strategies and other future events.

These forward-looking statements are based upon management’s current expectations and assumptions, and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: our limited operating history; our significant net losses incurred since inception and the likelihood of incurring additional losses for the foreseeable future; our need for substantial additional funding; the early stage of development of many of our product candidates and the possibility that our product candidates may fail in development; our dependence on the success of our current product candidates; our ability to leverage our technology platform to enable more informed drug research and development; legal and regulatory risks; intellectual property-related risks; and those risks, uncertainties and other factors discussed under the caption “Risk Factors” and elsewhere in Eikon’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission (“SEC”) on August 13, 2026, and in other public filings with the SEC in the future.

As a result, you should not place undue reliance on any forward-looking statements. The forward-looking statements made in this press release speak only as of the date of this press release, and Eikon undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law.

Contacts:

Investors
Alfred “Freddie” Bowie, Ph.D., CFO
ir@eikontx.com

Media
Colin Sanford
colin@bioscribe.com

• CEO Roger M. Perlmutter, M.D., Ph.D., to participate in Guggenheim 3^rd Annual Healthcare Innovation Conference Fireside Chat and JP Morgan Biotech Call series
• CMO Roy Baynes, M.D., Ph.D., to participate in Morgan Stanley Biotech Webcast discussing new data and the evolving synthetic lethality landscape

MILLBRAE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) — Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon Therapeutics, will participate in the JP Morgan Chase Biotech Call series and a Guggenheim Investor Conference as listed below:

Event: JP Morgan Biotech Call Series
Location: Boston, MA
Date & Time: November 6, 2026 at 2:00 pm EST
Format: Presentation

Event: Guggenheim 3rd Annual Healthcare Innovation Conference
Location: Boston, MA
Date & Time: November 10, 2026 at 8:00 pm EST
Format: Fireside Chat

In addition, Chief Medical Officer, Roy Baynes, M.D., Ph.D., will participate in the Morgan Stanley Biotech Webcast in November:

Event: Post-ESMO: New Data & the Evolving Synthetic Lethality Landscape
Location: New York City, NY
Date & Time: November 3, 2026 at 10:30 am EST
Format: Call

Live audio/video webcasts of these presentations will be accessible through Eikon’s investor relations website at investors.eikontx.com, with an archived edition of the session available later that day and accessible for approximately 30 days after the live event.

About Eikon Therapeutics
Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully integrated organization developing innovative medicines to address serious unmet medical needs. Eikon’s initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers. Eikon deploys its technology platform, including its proprietary single molecule tracking system, to develop internally derived novel therapies, while also leveraging the deep expertise of its management team to in-license promising assets. Eikon’s vision is to become a generational leader by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. For more information, visit www.eikontx.com.

Forward-Looking/Safe Harbor Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts are hereby identified as forward-looking statements for this purpose. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the therapeutic potential, safety, and efficacy of Eikon’s product candidates; the potential to further develop Eikon’s product candidates; the timing for anticipated data readouts; expected milestones and business objectives, including Eikon’s anticipated presentations at the 2026 ESMO Congress; and other statements regarding Eikon’s future operations, financial performance, financial position, prospects, objectives, strategies and other future events.

These forward-looking statements are based upon management’s current expectations and assumptions, and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: our limited operating history; our significant net losses incurred since inception and the likelihood of incurring additional losses for the foreseeable future; our need for substantial additional funding; the early stage of development of many of our product candidates and the possibility that our product candidates may fail in development; our dependence on the success of our current product candidates; our ability to leverage our technology platform to enable more informed drug research and development; legal and regulatory risks; intellectual property-related risks; and those risks, uncertainties and other factors discussed under the caption “Risk Factors” and elsewhere in Eikon’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission (“SEC”) on August 13, 2026, and in other public filings with the SEC in the future.

As a result, you should not place undue reliance on any forward-looking statements. The forward-looking statements made in this press release speak only as of the date of this press release, and Eikon undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law.

Contacts:

Investors
Alfred “Freddie” Bowie, Ph.D., CFO
ir@eikontx.com

Media
Colin Sanford
colin@bioscribe.com

SOUTHAMPTON, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) — Environmental Tectonics Corporation (OTCID: ETCC) (“ETC” or the “Company”) was named to TIME’s annual list of America’s Growth Leaders 2027, ranking 201 among the top 500 companies. This recognition distinguishes ETC for its outstanding growth, performance, and business momentum. 

TIME and market research firm Statista, determined America’s Growth Leaders through an analysis of publicly traded companies headquartered in the U.S. Each company was evaluated based on revenue growth, stock performance, and financial stability.

ETC was also recognized in the Philadelphia Business Journal’s 2026 FAST 50 list, which highlights the fastest-growing companies in the Greater Philadelphia region. This is the second consecutive year that the Company has been recognized, ranking seventh both years.

Robert Laurent, ETC’s President and CEO stated, “Being named one of TIME’s America’s Growth Leaders is an indicator of the success of the strategic efforts of our entire team, in each of our business units. We are equally honored to be recognized as one of the fastest growing companies in the Greater Philadelphia region for the second year in a row.”

About ETC

ETC designs, manufactures, and sells software-driven products and services used to recreate and monitor the physiological effects of motion on humans, and equipment to control, modify, simulate and measure environmental conditions. Our products include aircrew training systems (aeromedical, tactical combat, and general), disaster management systems, sterilizers (steam and gas), environmental testing and simulation systems, and other products that involve similar manufacturing techniques and engineering technologies. ETC’s unique ability to offer complete systems, designed and produced to high technical standards, sets it apart from its competition. ETC’s headquarters is in Southampton, PA. For more information about ETC, visit http://www.etcusa.com/.

Forward-looking Statements

This news release contains forward-looking statements, which are based on management’s expectations and are subject to uncertainties and changes in circumstances. Words and expressions reflecting something other than historical fact are intended to identify forward-looking statements, and these statements may include terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “future”, “predict”, “potential”, “intend”, or “continue”, and similar expressions. We base our forward-looking statements on our current expectations and projections about future events or future financial performance. Our forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about ETC and its subsidiaries that may cause actual results to be materially different from any future results implied by these forward-looking statements. We caution you not to place undue reliance on these forward-looking statements.

Contact:	Tim Kennedy, CFO
Phone:	(215) 355-9100
E-mail:	info@etcusa.com

SOUTHAMPTON, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) — Environmental Tectonics Corporation (OTCID: ETCC) (“ETC” or the “Company”) was named to TIME’s annual list of America’s Growth Leaders 2027, ranking 201 among the top 500 companies. This recognition distinguishes ETC for its outstanding growth, performance, and business momentum. 

TIME and market research firm Statista, determined America’s Growth Leaders through an analysis of publicly traded companies headquartered in the U.S. Each company was evaluated based on revenue growth, stock performance, and financial stability.

ETC was also recognized in the Philadelphia Business Journal’s 2026 FAST 50 list, which highlights the fastest-growing companies in the Greater Philadelphia region. This is the second consecutive year that the Company has been recognized, ranking seventh both years.

Robert Laurent, ETC’s President and CEO stated, “Being named one of TIME’s America’s Growth Leaders is an indicator of the success of the strategic efforts of our entire team, in each of our business units. We are equally honored to be recognized as one of the fastest growing companies in the Greater Philadelphia region for the second year in a row.”

About ETC

ETC designs, manufactures, and sells software-driven products and services used to recreate and monitor the physiological effects of motion on humans, and equipment to control, modify, simulate and measure environmental conditions. Our products include aircrew training systems (aeromedical, tactical combat, and general), disaster management systems, sterilizers (steam and gas), environmental testing and simulation systems, and other products that involve similar manufacturing techniques and engineering technologies. ETC’s unique ability to offer complete systems, designed and produced to high technical standards, sets it apart from its competition. ETC’s headquarters is in Southampton, PA. For more information about ETC, visit http://www.etcusa.com/.

Forward-looking Statements

This news release contains forward-looking statements, which are based on management’s expectations and are subject to uncertainties and changes in circumstances. Words and expressions reflecting something other than historical fact are intended to identify forward-looking statements, and these statements may include terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “future”, “predict”, “potential”, “intend”, or “continue”, and similar expressions. We base our forward-looking statements on our current expectations and projections about future events or future financial performance. Our forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about ETC and its subsidiaries that may cause actual results to be materially different from any future results implied by these forward-looking statements. We caution you not to place undue reliance on these forward-looking statements.

Contact:	Tim Kennedy, CFO
Phone:	(215) 355-9100
E-mail:	info@etcusa.com

Transaction in Own Shares

30 October, 2026

• • • • • • • • • • • • • • • •

Shell plc (the ‘Company’) announces that on 30 October, 2026 it purchased the following number of Shares for cancellation.

Aggregated information on Shares purchased according to trading venue:

Date of purchase	Number of Shares purchased	Highest price paid	Lowest price paid	Volume weighted average price paid per share	Venue	Currency
30/10/2026	735,554	£40.7450	£40.2900	£40.4974	LSE	GBP
30/10/2026	225,426	£40.7350	£40.2900	£40.5030	Chi-X (CXE)	GBP
30/10/2026	133,020	£40.7300	£40.3100	£40.4838	BATS (BXE)	GBP
30/10/2026	484,146	€49.0650	€48.4900	€48.7679	XAMS	EUR
30/10/2026	208,196	€49.0650	€48.5000	€48.7676	CBOE DXE	EUR
30/10/2026	21,118	€49.0650	€48.5750	€48.7651	TQEX	EUR

These share purchases form part of the on- and off-market limbs of the Company’s existing share buy-back programme announced on 29 October 2026.

In respect of this programme, BNP Paribas (with respect to the on-market limb) and Natixis (with respect to the off-market limb) will make trading decisions in relation to the securities independently of the Company for a period from 29 October 2026 up to and including 29 January 2027.

The on-market limb will be effected within certain pre-set parameters and in accordance with the Company’s general authority to repurchase shares on-market. The off-market limb will be effected in accordance with the Company’s general authority to repurchase shares off-market pursuant to the off-market buyback contract approved by its shareholders and the pre-set parameters set out therein. The programme will be conducted in accordance with Chapter 9 of the UK Listing Rules and Article 5 of the Market Abuse Regulation 596/2014/EU dealing with buy-back programmes (“EU MAR”) and EU MAR as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020) through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time (“UK MAR”) and the Commission Delegated Regulation (EU) 2016/1052 (the “EU MAR Delegated Regulation”) and the EU MAR Delegated Regulation as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020) through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time.

In accordance with EU MAR and UK MAR, a breakdown of the individual trades made by BNP Paribas and Natixis on behalf of the Company as a part of the buy-back programme is detailed below.  

Enquiries

Media: International +44 (0) 207 934 5550; U.S. and Canada: https://www.shell.us/about-us/news-and-insights/media/submit-an-inquiry.html

LEI number of Shell plc: 21380068P1DRHMJ8KU70

Classification: Acquisition or disposal of the issuer’s own shares

Attachment

• SHELL_RNS_Report_PDF-2026 10 30Cons

Transaction in Own Shares

30 October, 2026

• • • • • • • • • • • • • • • •

Shell plc (the ‘Company’) announces that on 30 October, 2026 it purchased the following number of Shares for cancellation.

Aggregated information on Shares purchased according to trading venue:

Date of purchase	Number of Shares purchased	Highest price paid	Lowest price paid	Volume weighted average price paid per share	Venue	Currency
30/10/2026	735,554	£40.7450	£40.2900	£40.4974	LSE	GBP
30/10/2026	225,426	£40.7350	£40.2900	£40.5030	Chi-X (CXE)	GBP
30/10/2026	133,020	£40.7300	£40.3100	£40.4838	BATS (BXE)	GBP
30/10/2026	484,146	€49.0650	€48.4900	€48.7679	XAMS	EUR
30/10/2026	208,196	€49.0650	€48.5000	€48.7676	CBOE DXE	EUR
30/10/2026	21,118	€49.0650	€48.5750	€48.7651	TQEX	EUR

These share purchases form part of the on- and off-market limbs of the Company’s existing share buy-back programme announced on 29 October 2026.

In respect of this programme, BNP Paribas (with respect to the on-market limb) and Natixis (with respect to the off-market limb) will make trading decisions in relation to the securities independently of the Company for a period from 29 October 2026 up to and including 29 January 2027.

The on-market limb will be effected within certain pre-set parameters and in accordance with the Company’s general authority to repurchase shares on-market. The off-market limb will be effected in accordance with the Company’s general authority to repurchase shares off-market pursuant to the off-market buyback contract approved by its shareholders and the pre-set parameters set out therein. The programme will be conducted in accordance with Chapter 9 of the UK Listing Rules and Article 5 of the Market Abuse Regulation 596/2014/EU dealing with buy-back programmes (“EU MAR”) and EU MAR as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020) through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time (“UK MAR”) and the Commission Delegated Regulation (EU) 2016/1052 (the “EU MAR Delegated Regulation”) and the EU MAR Delegated Regulation as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020) through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time.

In accordance with EU MAR and UK MAR, a breakdown of the individual trades made by BNP Paribas and Natixis on behalf of the Company as a part of the buy-back programme is detailed below.  

Enquiries

Media: International +44 (0) 207 934 5550; U.S. and Canada: https://www.shell.us/about-us/news-and-insights/media/submit-an-inquiry.html

LEI number of Shell plc: 21380068P1DRHMJ8KU70

Classification: Acquisition or disposal of the issuer’s own shares

Attachment

• SHELL_RNS_Report_PDF-2026 10 30Cons

RENK completes acquisition of David Brown Defence – Huddersfield center of excellence for submarine propulsion systems

• Transaction closed following regulatory clearances
• Acquisition of DBD will support the delivery of Global Combat Ship (Type 26)
• Global Combat Ship (Type 26) ecosystem is a key strategic platform with significant long-term program and aftermarket potential
• RENK Group expands its naval portfolio and strengthens its presence in the UK and the Five Eyes countries
• David Brown Defence operates as RENK UK Huddersfield
• Acquisition expands product offering on Challenger 2, 3 and Boxer, to RENK’s platform base

Augsburg / Huddersfield (West Yorkshire, UK), November 02, 2026 – RENK Group AG, a leading provider of propulsion solutions for the military sector, has completed the acquisition of David Brown Defence (DBD) from Stellex Capital Management. The agreement was signed on July 3, 2026 in London. All required regulatory clearances have now been obtained. As of today, DBD is part of the RENK Group and operates under the name RENK UK Huddersfield. Effective immediately, the Huddersfield site will serve as a center of excellence for submarine propulsion systems.

DBD complements RENK’s existing portfolio in three areas: main propulsion systems for naval vessels, low-noise and low-vibration propulsion technology for submarines, which is being added to RENK’s portfolio for the first time, as well as powerpacks and transmissions for wheeled and tracked vehicles. Together, these capabilities contribute to the characteristics of a defense powerhouse.

“We are pleased to welcome David Brown Defence to the RENK Group today. With the closing of this acquisition, we are bringing together outstanding technological and operational capabilities – and taking on responsibility for critical defense programs and the customers behind them. We take that responsibility seriously: they can rely on RENK to continue to deliver. As a European partner, we are committed to Huddersfield and to the UK defense industry, and together we will strengthen our ability to provide armed forces with the reliable propulsion solutions they need,” says Dr. Alexander Sagel, CEO of RENK Group AG.

Through this acquisition, the RENK Group gains access to long-term naval programs in the United Kingdom, Canada, Norway and Australia, as well as a broader presence in the Five Eyes countries. With the acquisition the RENK Group will support the delivery of Global Combat Ship (Type 26). The GCS is a key component in this regard, offering long-term program and aftermarket potential. In the land systems segment, RENK will expand product offering of armored vehicles to include British programs such as the Challenger 2, 3 and Boxer.

David Brown Defence’s substantial order backlog and robust pipeline, valued at over 700 million pounds from 2026 to 2030, demonstrate the company’s significant involvement in these programs. Additionally, there are operational and technological synergies arising from the shared use of manufacturing capacity, procurement, engineering and market access.

“Our 530-person team brings more than a century of engineering expertise to the table. As part of RENK Group, we can build on that heritage with an international network and a shared commitment to quality and reliability for our customers. We are pleased to embark on this next chapter together,” said Mike Helme, CEO of David Brown Defence.

The parties agreed not to disclose commercial terms. Barclays served as financial advisor and Linklaters as legal advisor to the RENK Group in connection with the transaction.

About the RENK Group AG

Headquartered in Augsburg, Germany, RENK Group AG is a globally leading manufacturer of mission-critical propulsion solutions across diverse military and civil end markets. Our product portfolio includes gear units, transmissions, power-packs, hybrid propulsion systems, suspension systems, slide bearings, couplings & clutches and test systems. With this broad product portfolio RENK Group AG serves, in particular, customers in industries for military vehicles, naval, civil marine, and industrial applications focused on energy. In the fiscal year 2025, RENK Group AG generated revenue of approximately EUR 1.4 billion. RENK Group AG has been listed on the Frankfurt Stock Exchange since February 7, 2024, and has been a member of the MDAX since March 24, 2025.

For further information, please visit www.renk.com

About David Brown Defence

David Brown Defence is a UK-based business specialising in high-precision engineered gear systems for both land defense and marine sectors. Headquartered in Huddersfield, the company employs around 530 people and plays a critical role in supporting key defense programs.

About Stellex Capital Management LLC

With offices in New York, London, Pittsburgh, and Detroit, Stellex Capital is a private equity firm with over $6.9 billion in AUM. Stellex seeks to identify and deploy capital in opportunities that stand to benefit from its operationally focused and hands-on approach to investing. Portfolio companies are supported by Stellex’s industry knowledge, operating capabilities, network of senior executives, strategic insights, and access to capital. Sectors of particular focus include aerospace & defence, government services, transportation & logistics, manufacturing, real economy & business services, food processing, and tech-enabled services.

Disclaimer

This Press Release contains forward-looking statements that are based on plans, expectations, estimates and projections of the management of RENK Group as at the date of this Press Release. These plans, expectations, estimates and projections depend on a variety of assumptions and are subject to unforeseeable events, uncertainties, known and unknown risks as well as other factors that may cause actual results or the actual financial situation, development or performance to differ from those expressed or implied in the forward-looking statements. RENK Group does not assume any obligation to update the forward-looking statements or make adjustments to them to reflect events or developments occurring after the date of this Press Release unless obliged by statutory law.

RENK Group AG Gögginger Str. 73 D-86159 Augsburg Deutschland  www.renk.com	Media Inquiries to: Fabian Klee Chief Communications and Marketing Officer fabian.klee@renk.com +49 160 7154 647	Investor Inquiries to: Team Investor Relations investors@renk.com
About the RENK Group AG Headquartered in Augsburg, Germany, RENK Group AG is a globally leading manufacturer of mission-critical propulsion solutions across diverse military and civil end markets. Our product portfolio includes gear units, transmissions, power-packs, hybrid propulsion systems, suspension systems, slide bearings, couplings & clutches and test systems. With this broad product portfolio RENK Group AG serves, in particular, customers in industries for military vehicles, naval, civil marine, and industrial applications focused on energy. In the fiscal year 2025, RENK Group AG generated revenue of approximately EUR 1.4 billion. RENK Group AG has been listed on the Frankfurt Stock Exchange since February 7, 2024, and has been a member of the MDAX since March 24, 2025.   For further information, please visit www.renk.com   Disclaimer This Press Release contains forward-looking statements that are based on plans, expectations, estimates and projections of the management of RENK Group as at the date of this Press Release. These plans, expectations, estimates and projections depend on a variety of assumptions and are subject to unforeseeable events, uncertainties, known and unknown risks as well as other factors that may cause actual results or the actual financial situation, development or performance to differ from those expressed or implied in the forward-looking statements. RENK Group does not assume any obligation to update the forward-looking statements or make adjustments to them to reflect events or developments occurring after the date of this Press Release unless obliged by statutory law.

RENK completes acquisition of David Brown Defence – Huddersfield center of excellence for submarine propulsion systems

• Transaction closed following regulatory clearances
• Acquisition of DBD will support the delivery of Global Combat Ship (Type 26)
• Global Combat Ship (Type 26) ecosystem is a key strategic platform with significant long-term program and aftermarket potential
• RENK Group expands its naval portfolio and strengthens its presence in the UK and the Five Eyes countries
• David Brown Defence operates as RENK UK Huddersfield
• Acquisition expands product offering on Challenger 2, 3 and Boxer, to RENK’s platform base

Augsburg / Huddersfield (West Yorkshire, UK), November 02, 2026 – RENK Group AG, a leading provider of propulsion solutions for the military sector, has completed the acquisition of David Brown Defence (DBD) from Stellex Capital Management. The agreement was signed on July 3, 2026 in London. All required regulatory clearances have now been obtained. As of today, DBD is part of the RENK Group and operates under the name RENK UK Huddersfield. Effective immediately, the Huddersfield site will serve as a center of excellence for submarine propulsion systems.

DBD complements RENK’s existing portfolio in three areas: main propulsion systems for naval vessels, low-noise and low-vibration propulsion technology for submarines, which is being added to RENK’s portfolio for the first time, as well as powerpacks and transmissions for wheeled and tracked vehicles. Together, these capabilities contribute to the characteristics of a defense powerhouse.

“We are pleased to welcome David Brown Defence to the RENK Group today. With the closing of this acquisition, we are bringing together outstanding technological and operational capabilities – and taking on responsibility for critical defense programs and the customers behind them. We take that responsibility seriously: they can rely on RENK to continue to deliver. As a European partner, we are committed to Huddersfield and to the UK defense industry, and together we will strengthen our ability to provide armed forces with the reliable propulsion solutions they need,” says Dr. Alexander Sagel, CEO of RENK Group AG.

Through this acquisition, the RENK Group gains access to long-term naval programs in the United Kingdom, Canada, Norway and Australia, as well as a broader presence in the Five Eyes countries. With the acquisition the RENK Group will support the delivery of Global Combat Ship (Type 26). The GCS is a key component in this regard, offering long-term program and aftermarket potential. In the land systems segment, RENK will expand product offering of armored vehicles to include British programs such as the Challenger 2, 3 and Boxer.

David Brown Defence’s substantial order backlog and robust pipeline, valued at over 700 million pounds from 2026 to 2030, demonstrate the company’s significant involvement in these programs. Additionally, there are operational and technological synergies arising from the shared use of manufacturing capacity, procurement, engineering and market access.

“Our 530-person team brings more than a century of engineering expertise to the table. As part of RENK Group, we can build on that heritage with an international network and a shared commitment to quality and reliability for our customers. We are pleased to embark on this next chapter together,” said Mike Helme, CEO of David Brown Defence.

The parties agreed not to disclose commercial terms. Barclays served as financial advisor and Linklaters as legal advisor to the RENK Group in connection with the transaction.

About the RENK Group AG

Headquartered in Augsburg, Germany, RENK Group AG is a globally leading manufacturer of mission-critical propulsion solutions across diverse military and civil end markets. Our product portfolio includes gear units, transmissions, power-packs, hybrid propulsion systems, suspension systems, slide bearings, couplings & clutches and test systems. With this broad product portfolio RENK Group AG serves, in particular, customers in industries for military vehicles, naval, civil marine, and industrial applications focused on energy. In the fiscal year 2025, RENK Group AG generated revenue of approximately EUR 1.4 billion. RENK Group AG has been listed on the Frankfurt Stock Exchange since February 7, 2024, and has been a member of the MDAX since March 24, 2025.

For further information, please visit www.renk.com

About David Brown Defence

David Brown Defence is a UK-based business specialising in high-precision engineered gear systems for both land defense and marine sectors. Headquartered in Huddersfield, the company employs around 530 people and plays a critical role in supporting key defense programs.

About Stellex Capital Management LLC

With offices in New York, London, Pittsburgh, and Detroit, Stellex Capital is a private equity firm with over $6.9 billion in AUM. Stellex seeks to identify and deploy capital in opportunities that stand to benefit from its operationally focused and hands-on approach to investing. Portfolio companies are supported by Stellex’s industry knowledge, operating capabilities, network of senior executives, strategic insights, and access to capital. Sectors of particular focus include aerospace & defence, government services, transportation & logistics, manufacturing, real economy & business services, food processing, and tech-enabled services.

Disclaimer

This Press Release contains forward-looking statements that are based on plans, expectations, estimates and projections of the management of RENK Group as at the date of this Press Release. These plans, expectations, estimates and projections depend on a variety of assumptions and are subject to unforeseeable events, uncertainties, known and unknown risks as well as other factors that may cause actual results or the actual financial situation, development or performance to differ from those expressed or implied in the forward-looking statements. RENK Group does not assume any obligation to update the forward-looking statements or make adjustments to them to reflect events or developments occurring after the date of this Press Release unless obliged by statutory law.

RENK Group AG Gögginger Str. 73 D-86159 Augsburg Deutschland  www.renk.com	Media Inquiries to: Fabian Klee Chief Communications and Marketing Officer fabian.klee@renk.com +49 160 7154 647	Investor Inquiries to: Team Investor Relations investors@renk.com
About the RENK Group AG Headquartered in Augsburg, Germany, RENK Group AG is a globally leading manufacturer of mission-critical propulsion solutions across diverse military and civil end markets. Our product portfolio includes gear units, transmissions, power-packs, hybrid propulsion systems, suspension systems, slide bearings, couplings & clutches and test systems. With this broad product portfolio RENK Group AG serves, in particular, customers in industries for military vehicles, naval, civil marine, and industrial applications focused on energy. In the fiscal year 2025, RENK Group AG generated revenue of approximately EUR 1.4 billion. RENK Group AG has been listed on the Frankfurt Stock Exchange since February 7, 2024, and has been a member of the MDAX since March 24, 2025.   For further information, please visit www.renk.com   Disclaimer This Press Release contains forward-looking statements that are based on plans, expectations, estimates and projections of the management of RENK Group as at the date of this Press Release. These plans, expectations, estimates and projections depend on a variety of assumptions and are subject to unforeseeable events, uncertainties, known and unknown risks as well as other factors that may cause actual results or the actual financial situation, development or performance to differ from those expressed or implied in the forward-looking statements. RENK Group does not assume any obligation to update the forward-looking statements or make adjustments to them to reflect events or developments occurring after the date of this Press Release unless obliged by statutory law.

PARAMUS, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) — ALEXANDER’S, INC. (New York Stock Exchange: ALX) filed its Form 10-Q for the quarter ended September 30, 2026 today and reported:

Third Quarter 2026 Financial Results

Net income for the quarter ended September 30, 2026 was $27.4 million, or $5.33 per diluted share, compared to $6.0 million, or $1.16 per diluted share for the quarter ended September 30, 2025.

Funds from operations (“FFO”) (non-GAAP) for the quarter ended September 30, 2026 was $36.3 million, or $7.07 per diluted share, compared to $14.9 million, or $2.91 per diluted share for the quarter ended September 30, 2025.

Nine Months Ended September 30, 2026 Financial Results

Net income for the nine months ended September 30, 2026 was $187.4 million, or $36.48 per diluted share, compared to $24.4 million, or $4.75 per diluted share for the nine months ended September 30, 2025. Net income for the nine months ended September 30, 2026 included $148.0 million, or $28.81 per diluted share, of income as a result of a net gain from the sale of the Rego Park I property.

FFO (non-GAAP) for the nine months ended September 30, 2026 was $65.3 million, or $12.70 per diluted share, compared to $50.5 million, or $9.84 per diluted share for the nine months ended September 30, 2025.

Alexander’s, Inc. is a real estate investment trust which has four properties in New York City.

CONTACT:
GARY HANSEN
(201) 587-8541

Certain statements contained herein may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. For a discussion of factors that could materially affect the outcome of our forward-looking statements and our future results and financial condition, see “Risk Factors” in Part I, Item 1A, of our Annual Report on Form 10-K for the year ended December 31, 2025. Such factors include, among others, risks associated with the timing of and costs associated with property improvements, financing commitments, the financial condition of our tenants, and general competitive factors.

(tables to follow)
ALEXANDER’S, INC.
FINANCIAL RESULTS FOR THE QUARTERS ENDED SEPTEMBER 30, 2026 AND 2025
Below is a table of selected financial results.
	QUARTER ENDED SEPTEMBER 30,
(Amounts in thousands, except share and per share amounts)		2026				2025
Revenues	$	72,056			$	53,424
Net income	$	27,404			$	5,968
Net income per common share – basic and diluted	$	5.33			$	1.16
Weighted average shares outstanding – basic and diluted		5,139,491				5,135,956
FFO (non-GAAP)	$	36,349			$	14,920
FFO per diluted share (non-GAAP)	$	7.07			$	2.91
Weighted average shares used in computing FFO per diluted share		5,139,491				5,135,956

The following table reconciles net income to FFO (non-GAAP):

	QUARTER ENDED SEPTEMBER 30,
(Amounts in thousands, except share and per share amounts)		2026				2025
Net income	$	27,404			$	5,968
Depreciation and amortization of real property		8,945				8,952
FFO (non-GAAP)	$	36,349			$	14,920
FFO per diluted share (non-GAAP)	$	7.07			$	2.91
Weighted average shares used in computing FFO per diluted share		5,139,491				5,135,956

ALEXANDER’S, INC.
FINANCIAL RESULTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025
Below is a table of selected financial results.
	NINE MONTHS ENDED SEPTEMBER 30,
(Amounts in thousands, except share and per share amounts)		2026				2025
Revenues	$	180,179			$	159,928
Net income	$	187,428			$	24,400
Net income per common share – basic and diluted	$	36.48			$	4.75
Weighted average shares outstanding – basic and diluted		5,137,678				5,134,705
FFO (non-GAAP)	$	65,251			$	50,524
FFO per diluted share (non-GAAP)	$	12.70			$	9.84
Weighted average shares used in computing FFO per diluted share		5,137,678				5,134,705

The following table reconciles net income to FFO (non-GAAP):

	NINE MONTHS ENDED SEPTEMBER 30,
(Amounts in thousands, except share and per share amounts)		2026				2025
Net income	$	187,428			$	24,400
Depreciation and amortization of real property		25,825				26,124
Net gain on sale of real estate		(148,002	)			—
FFO (non-GAAP)	$	65,251			$	50,524
FFO per diluted share (non-GAAP)	$	12.70			$	9.84
Weighted average shares used in computing FFO per diluted share		5,137,678				5,134,705

FFO is computed in accordance with the definition adopted by the Board of Governors of the National Association of Real Estate Investment Trusts (“NAREIT”). NAREIT defines FFO as GAAP net income or loss adjusted to exclude net gains from sales of certain real estate assets, real estate impairment losses, depreciation and amortization expense from real estate assets and other specified items, including the pro rata share of such adjustments of unconsolidated subsidiaries. FFO and FFO per diluted share are non-GAAP financial measures used by management, investors and analysts to facilitate meaningful comparisons of operating performance between periods and among our peers because it excludes the effect of real estate depreciation and amortization and net gains on sales, which are based on historical costs and implicitly assume that the value of real estate diminishes predictably over time, rather than fluctuating based on existing market conditions. FFO does not represent cash generated from operating activities and is not necessarily indicative of cash available to fund cash requirements and should not be considered as an alternative to net income as a performance measure or cash flow as a liquidity measure. FFO may not be comparable to similarly titled measures employed by other companies. A reconciliation of net income to FFO is provided above.